CURE

Global X S&P Biotech ETF

Thematic Growth — People & Demographics

REASONS TO CONSIDER

High Growth Potential
Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls
Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure
CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

KEY INFORMATION

As of 30 August 2024

Exchange Code	CURE
IRESS	CURE.AXW
ISIN	AU0000028110
Issuer	Global X Management (AUS) Limited
Domicile	Australia
Base Currency	Australian Dollar
Currency Hedged	No
Inception Date	08 Nov 2018
Mgt. Fee (% p.a.)	0.45
Fund Size ($mn)	42
NAV per Unit ($)	50.96

*Calculated on the Net Asset Value (NAV) of the Fund. All fees and costs are inclusive of GST. Refer to the PDS for a complete list of fees and costs.

PERFORMANCE (%)

Trailing Return*	1M	YTD	1Y	3Y	5Y	Since Inception
CURE	-1.5%	13.9%	21.8%	-6.5%	3.5%	4.2%
Index	-1.5%	14.3%	22.5%	-6.2%	3.9%	4.7%
S&P 500	-1.5%	19.9%	20.8%	11.6%	15.3%	15.5%

Calendar Year Return*	2023	2022	2021	2020	2019
CURE	6.8%	-20.6%	-15.8%	33.6%	32.0%
Index	7.1%	-20.3%	-15.5%	34.8%	32.5%
S&P 500	24.9%	-12.6%	36.0%	7.3%	30.9%

* Total returns in Australian dollar terms. Returns for periods greater than one year are annualised. Fund inception date 8 Nov 2018. Note that index and fund returns shown are 'net total return', meaning dividends are reinvested net of any withholding taxes across the entire index in proportion to prevailing index weights. Index returns are theoretical and do not include the impact of fees or costs of investing. Past performance is not a reliable indicator of future results.

INDUSTRY BREAKDOWN (%)

Biotechnology	79.7
Pharmaceuticals	12.8
Healthcare-Products	7.4

MARKET CAPITALISATION BREAKDOWN (%)

Large Cap	41.4
Mid Cap	43.8
Small Cap	14.8

115 PITT STREET
9TH FLOOR
SYDNEY, NSW 2000

(61) 2 8311 3488
INFO@GLOBALXETFS.COM.AU
WWW.GLOBALXETFS.COM.AU

TOP 10 HOLDINGS (%) Holdings Subject to Change

Exact Sciences Corp	3.7	Alnylam Pharmaceuticals Inc	2.9
United Therapeutics Corp	3.2	Regeneron Pharmaceuticals Inc	2.9
Gilead Sciences Inc	3.0	Amgen Inc	2.8
AbbVie Inc	2.9	BioMarin Pharmaceutical Inc	2.7
Viking Therapeutics Inc	2.9	Sarepta Therapeutics Inc	2.7

INDEX DESCRIPTION

The S&P Biotechnology Select Industry Index tracks the performance of U.S. listed companies that are classified as belonging to the GICS biotechnology sub-industry and meet certain market capitalisation and liquidity requirements.

Constituents are equally weighted subject to liquidity and the index rebalances quarterly.

PORTFOLIO STATISTICS

Number of Holdings	135
Median Market Cap ($bn)	3.1
P/E Ratio^	N/A
P/B Ratio^	5.2

DISTRIBUTION DETAILS

Distribution Frequency	Annually
Latest Distribution	$0.02
Latest Distribution Date	30 Jun 2022
12-Month Yield (%)	N/A

BENCHMARK DETAILS

Name	S&P Biotechnology Select Industry Index
Base Currency	US Dollar
Rebalancing Frequency	Quarterly
Weighting Scheme	Modified Equal Weighted

^ Weighted average of price divided by earnings (P/E) and book value (P/B) per share. N/A where P/E Ratio is negative.

1 National Human Genome Research Institute, Nov 2021

The issuer of units in Global X S&P Biotech ETF (CURE) ARSN: 628 037 105 is the responsible entity of the Fund, being Global X Management (AUS) Limited (AFSL 466778) ("Global X"). The product disclosure statement (PDS) for the Fund contains all of the details of the offer of units in the Fund. Copies of the PDS are available from Global X Management (AUS) Limited or at www.globalxetfs.com.au. In respect of each retail product, Global X has prepared a target market determination (TMD) which describes the type of customers who the relevant retail product is likely to be appropriate for. The TMD also specifies distribution conditions and restrictions that will help ensure the relevant product is likely to reach customers in the target market. Each TMD is available at www.globalxetfs.com.au. The information provided in this document is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information in this document, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. None of Global X, the group of companies which Mirae Asset Global Investments Co., Ltd is the parent, or their respective directors, employees or agents guarantees the performance of any products issued by Global X or the repayment of capital or any particular rate of return therefrom. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance. Standard & Poor's S&P Indices are trademarks of Standard & Poor's Financial Services LLC. "S&P", as used in the term S&P 500, is a trademark of Standard & Poor's Financial Services LLC ("S&P") respectively and has been licensed for use by Global X. Global X products are not sponsored, endorsed, sold or promoted by S&P, and S&P does not make any representation regarding the advisability of investing in ETFs products.

115 PITT STREET
9TH FLOOR
SYDNEY, NSW 2000

(61) 2 8311 3488
INFO@GLOBALXETFS.COM.AU
WWW.GLOBALXETFS.COM.AU